Ruderman · Diabetes 2006 · narrative review with preclinical animal and in vitro experiments · n=?

Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome.

Cited 187 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal model (knockout mice), in vitro tissue assays, and narrative review without human clinical data.

PubMed 17130644 · doi:10.2337/db06-s007 · record verified 2026-08-29

What was done

The authors reviewed and reported data on the regulation of AMP-activated protein kinase (AMPK) by interleukin-6 (IL-6). Experiments examined AMPK activity in vivo, in incubated rodent muscles, and in cultured adipocytes following IL-6 exposure. Baseline and exercise-stimulated AMPK activity, exercise tolerance, and metabolic profiles were assessed in control versus IL-6 knockout (KO) mice at 3 and 9 months of age.

What was found

The abstract reports no exact numeric values. Qualitatively, IL-6 administration increased AMPK activity in rodent skeletal muscle and adipose tissue both in vivo and in vitro. In 3-month-old IL-6 KO mice, resting AMPK activity and exercise-induced AMPK increases were diminished in muscle and adipose tissue compared with controls, alongside impaired exercise capacity and fatty acid oxidation. By 9 months of age, IL-6 KO mice developed obesity, dyslipidemia, and impaired glucose tolerance.

Why it matters

This work outlines a mechanistic link between exercise-induced muscle cytokine release (IL-6) and systemic metabolic regulation via AMPK, suggesting a pathway through which physical activity may protect against metabolic syndrome.

Limits

The abstract provides no sample sizes, numerical effect sizes, or statistical metrics. The findings rely strictly on rodent knockout models and isolated cell/tissue preparations, leaving the direct clinical relevance and causal role in humans unconfirmed.

Cited by